Japan Fortnightly Update: Spiked
SHORT-LIVED - The much-lauded 'breakout' in the Nikkei 225 (NKY INDEX) at the end of last month proved to be short-lived. As measured by Total...
570 Views
Symbio Confirms Treakisym’s In-House Commercialization Post Patent Expiration in 2020e
Significantly reduces execution risk for an operational turnaround in 2021e As highlighted in previous notes ("Symbio Pharma (4582 JP) -Â Gross...
385 Views
Treakisym to Be Used as a Pre-Treatment To CAR-T Therapy
Announcement – Symbio Pharmaceuticals (4582 JP) on September 27, 2018, announced that it has filed a partial change application for marketing...
906 Views
Growth Drivers on Track – Operational Turnaround Expected in 2021
We reiterate our “Overweight” rating on the stock post 1H FY18 (YE Dec-18) earnings1H FY18 Results Highlights Symbio reported an increase in 1H...
491 Views
Symbio Pharma (4582 JP) -Â Gross Margin Expansion Led Operational Turnaround in 2021
2020 – an inflection point for Symbio Treakisym (bendamustine), Symbio’s only revenue driver currently, is marketed by Eisai in Japan for r/r NHL....
259 Views